Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Viatris Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.65, while Viatris Inc trades at $16.06 (market cap $18.49B). The key difference: Viatris Inc pays a 2.98% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Viatris Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | VTRS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $17.86 |
52-Week Low | $24.83 | $9.49 |
Market Cap | — | $18.49B |
Enterprise Value | — | $30.61B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.59 with no change in the last 24 hours. Technical indicators show a bullish trend with moving averages supporting upward momentum while oscillators remain neutral. The stock faces resistance at $26 with support at $25-26 levels. Recent dividend activity includes three payments in 2026 ranging from $0.13 to $0.14 per share.
The bullish technical setup suggests potential for near-term upside if resistance levels are breached. However, key financial ratios remain unavailable for fundamental assessment. Emerging market debt exposure presents both yield opportunities and volatility risks, requiring careful monitoring of global economic conditions and interest rate trends.
Viatris (VTRS) trades at $16.04, down 1.47% on the day, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.69 exceeding expectations by 14.8%. Recent FDA approval for Gwyn Lo contraceptive patch and divestiture of Tyrvaya nasal spray demonstrate strategic portfolio optimization. Revenue trends show stabilization after declining from $16.3B in 2022 to $14.3B in 2025, with 2026 projections at $14.7B.
While Viatris shows operational strength with consistent cash flow generation and debt reduction, the company faces profitability challenges with negative net income margins and elevated P/E ratio of 236.2. Analyst sentiment is cautiously optimistic with 30.8% buy ratings, though the majority (61.5%) recommend hold. Key risks include ongoing margin pressure, generic drug pricing headwinds, and execution of strategic initiatives amid competitive pharmaceutical landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
